vs. Hetero, Aurobindo, Vivimed
Payout Range
Varies
Deadline
6/2/2026
Time Left
35 days
Three separate class action settlements have been reached in a massive multidistrict litigation over contaminated blood pressure medications. The lawsuit alleged that certain generic versions of valsartan, losartan, and irbesartan were manufactured using processes that created nitrosamine impurities, which are classified as probable human carcinogens. The contamination led to a series of nationwide drug recalls starting in 2018. These settlements resolve economic loss claims for consumers and insurers who overpaid for these drugs.
No specific eligibility requirements listed. Review the official settlement terms for complete criteria.
Individuals in the United States who paid for retail purchases of valsartan, losartan, or irbesartan during the relevant time periods.
This settlement has the following claim path.
Documentation is encouraged but not always required for claims.
This settlement accepts online and mail claim submissions. Pick whichever is easier.
ClaimHawk is an independent service. Review the official settlement site for legally binding terms.